Table 7.
Risk of disease recurrence by nodal status in trials of dose-dense chemotherapy
Node negative | 1–3 nodes | >3 nodes | |
---|---|---|---|
TACT2 | 1·00 (0·78–1·28) | 0·87 (0·69–1·09) | 0·97 (0·72–1·30) |
GIM215* | N/A | 0·88 (0·67–1·11) | 0·68 (0·54–0·86) |
AGO ETC17 | N/A | N/A | 0·72 (0·59–0·87) |
Data are hazard ratios (95% CI) for the primary endpoint (recurrence) by nodal subgroups. N/A=not applicable.
Data supplied by authors on request; similar data for CALGB 9741 were unavailable.